Darrel Randle
Papers
2
Total Citations
9
H-Index
1
About
Darrel Randle is a clinical researcher focused on optimizing surgical recovery in urologic oncology, particularly for patients undergoing radical cystectomy for bladder cancer. His work centers on the integration of pharmacologic agents into Enhanced Recovery After Surgery (ERAS) protocols to reduce postoperative morbidity and hospital resource utilization. Randle’s most prominent contribution is demonstrating that alvimopan, a peripherally acting mu-opioid receptor antagonist, significantly decreases length of hospital stay when used as part of a standardized ERAS pathway. His 2021 study, with 8 citations, analyzed 296 consecutive patients and provided strong retrospective evidence that this multimodal approach accelerates gastrointestinal recovery and shortens hospitalization. Randle’s research addresses a critical clinical challenge—prolonged hospital stays after major pelvic surgery—and offers a practical, evidence-based solution. By highlighting alvimopan as an essential component rather than an optional adjunct, his work has helped shape perioperative protocols at major institutions. For students and clinicians interested in surgical quality improvement, ERAS implementation, or bladder cancer care, Randle’s findings represent a clear example of how targeted interventions can translate into meaningful patient outcomes and system-level efficiency.
Research Focus
Key Achievements
Top Papers
- 1
- 2